29 December 2024 : Clinical Research
Prospective Analysis of Central Nervous System Infection Risks in Varicella-Zoster Virus Reactivation Cases: A Single-Center Prospective Study of 1030 Cases
Jun Wang ABEG 1*, Yanrong Yuan BEF 1, Huili Liu BCF 1, Yan Zhang EF 1, Yongxing Yan ACDG 1DOI: 10.12659/MSM.945835
Med Sci Monit 2024; 30:e945835
Table 1 Clinical characteristics between HZ group and VZV-associated CNS infection group.
| HZ group (n=990) | VZV-associated CNS infection group (n=40) | t/χ2 | P | |
|---|---|---|---|---|
| Age (x±SD) (years) | 60.7±15.3 | 55.7±15.0 | 2.033 | 0.042 |
| Sex (n (%)) | ||||
| Male | 454 (45.9) | 23 (57.5) | 2.096 | 0.148 |
| Female | 536 (54.1) | 17 (42.5) | ||
| Concomitant diseases (n (%)) | ||||
| Hypertension | 321 (32.4) | 15 (37.5) | 0.451 | 0.502 |
| Type 2 diabetes | 94 (9.5) | 4 (10.0) | 0.011 | 0.915 |
| Coronary heart disease | 25 (2.5) | 0 (0) | NA | NA |
| Heart failure | 0 (0) | 0 (0) | NA | NA |
| Atrial fibrillation | 7 (0.7) | 0 (0) | NA | NA |
| Tumors | 63 (6.4) | 2 (5.0) | 0.121 | 0.728 |
| Stroke | 11 (1.1) | 0 (0) | NA | NA |
| Chronic obstructive pulmonary disease | 15 (1.5) | 0 (0) | NA | NA |
| Chronic liver disease | 10 (1.0) | 1 (2.5) | 0.808 | 0.369 |
| Chronic kidney disease | 9 (0.9) | 1 (2.5) | 1.012 | 0.314 |
| Hematologic malignancies | 5 (0.5) | 1 (2.5) | 2.642 | 0.104 |
| Gout | 4 (0.4) | 0 (0) | NA | NA |
| Hyperthyroidism | 3 (0.3) | 0 (0) | NA | NA |
| Hashimoto thyroiditis | 9 (0.9) | 0 (0) | NA | NA |
| Hypothyroidism | 11 (1.1) | 1 (2.5) | 0.644 | 0.422 |
| Immunological diseases | 24 (2.4) | 2 (5.0) | 1.037 | 0.309 |
| Immunosuppressant use | 4 (0.4) | 0 (0) | NA | NA |
| Herpes site (n (%)) | ||||
| Head and neck | 515 (52.0) | 30 (75.0) | 14.761 | 0.002 |
| Chest and back | 173 (17.5) | 9 (22.5) | ||
| Waist and abdomen | 177 (17.9) | 0 (0) | ||
| Limb | 125 (12.6) | 1 (2.5) | ||
| Interval from onset to treatment (x±SD) (days) | 5.3±2.6 | 6.5±3.1 | 2.867 | 0.004 |